Is Wixela Inhuber Used for COPD?
Yes, Wixela Inhuber (fluticasone propionate and salmeterol inhalation powder) is FDA-approved for maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It combines an inhaled corticosteroid (fluticasone) to reduce inflammation with a long-acting beta-agonist (salmeterol) to relax airway muscles, helping improve lung function and reduce exacerbations.[1][2]
How Does Wixela Inhuber Compare to Advair Diskus?
Wixela Inhuber is the first interchangeable generic version of Advair Diskus, matching its 100/50 mcg, 250/50 mcg, and 500/50 mcg strengths. Clinical studies showed bioequivalence in delivery and absorption, with similar efficacy for COPD symptom control.[1][3]
What COPD Symptoms Does It Target?
It eases shortness of breath, wheezing, coughing, and frequent flare-ups in moderate to severe COPD patients. Guidelines from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommend such combination inhalers for patients with persistent symptoms despite short-acting bronchodilators.[2][4]
Who Should Use Wixela for COPD?
Prescribed for adults with COPD needing long-term control, not acute relief. Not for asthma as primary therapy or in patients with acute bronchospasm. Doctors assess based on spirometry (FEV1) and exacerbation history.[1][2]
Common Side Effects in COPD Patients
Oral thrush, pneumonia risk (higher in COPD), headache, throat irritation, and muscle cramps. Rinse mouth after use to cut thrush odds. Monitor for worsening breathing or allergic reactions.[1][5]
When Does Wixela's Patent or Exclusivity Expire?
As a generic, Wixela entered after Advair's key patents expired in 2019 (U.S. Patent No. 5,760,584 for dry powder inhaler). No remaining brand exclusivity blocks further generics.[6]
[1]: FDA Label for Wixela Inhuber
[2]: GOLD 2024 Report
[3]: FDA Interchangeability Designation
[4]: American Thoracic Society COPD Guidelines
[5]: Drugs.com Wixela Side Effects
[6]: DrugPatentWatch.com - Advair Diskus Patents